TAPT1 inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the TAPT1 protein, also known as transmembrane anterior posterior transformation 1. TAPT1 is a protein with important roles in cellular processes, particularly in the development and maintenance of cellular structures. TAPT1 has been implicated in the regulation of ciliogenesis, the process by which cilia-hair-like structures on the surface of cells-are formed. Cilia are critical for cell signaling, movement, and maintaining cellular communication. TAPT1 is thought to help organize the assembly of ciliary components, contributing to proper cilia function and structural integrity. By inhibiting TAPT1, these compounds disrupt the protein's role in the formation or function of cilia, potentially leading to altered cellular signaling and structural defects in ciliary components.
Research into TAPT1 inhibitors offers valuable insights into the molecular mechanisms involved in cilia formation and function, as well as the broader role of TAPT1 in cellular architecture. By inhibiting TAPT1, scientists can explore the specific contribution of this protein to cilia assembly and how its absence affects various signaling pathways that rely on functional cilia. Additionally, TAPT1 inhibitors serve as tools to understand the structural organization of cellular components and how disruptions in TAPT1 activity impact processes such as cell division, tissue organization, and intracellular transport. These inhibitors help elucidate the intricate relationship between cellular structure and function, contributing to a deeper understanding of the molecular machinery involved in maintaining cellular integrity and the role of TAPT1 in ensuring proper cellular development and communication across different tissue types.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
Inhibits PI3K, leading to reduced phosphorylation of downstream targets. Alters TAPT1 association with membrane components. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Targets PI3K, leading to disruption of TAPT1-related vesicle transport due to the loss of PIP3. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Inhibits mTORC1, thus reducing TAPT1-mediated protein synthesis due to restricted 4E-BP1 phosphorylation. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
Inhibits p38 MAPK; reduces TAPT1-dependent cytoskeletal remodeling through reduced HSP27 phosphorylation. | ||||||
STO-609 | 52029-86-4 | sc-507444 | 5 mg | $140.00 | ||
Inhibits CaMKK; impacts TAPT1-related calcium signaling by disrupting AMPK activation. | ||||||
BML-275 | 866405-64-3 | sc-200689 sc-200689A | 5 mg 25 mg | $94.00 $348.00 | 69 | |
Inhibits AMPK; interrupts TAPT1 interaction with calcium channels by preventing phosphorylation of channel components. | ||||||
Akt Inhibitor VIII, Isozyme-Selective, Akti-1/2 | 612847-09-3 | sc-202048 sc-202048A | 1 mg 5 mg | $204.00 $265.00 | 29 | |
Inhibits Akt; increases TAPT1 degradation due to reduced inhibition of proteasomal components. | ||||||
GSK 650394 | 890842-28-1 | sc-361201 sc-361201A | 10 mg 50 mg | $183.00 $754.00 | 8 | |
Inhibits SGK; disrupts TAPT1 function in ion homeostasis due to altered ENaC activity. | ||||||
MK-2206 dihydrochloride | 1032350-13-2 | sc-364537 sc-364537A | 5 mg 10 mg | $178.00 $325.00 | 67 | |
Inhibits Akt; impacts TAPT1's role in protein trafficking by altering Rab GTPase activity. | ||||||
BAY 11-7082 | 19542-67-7 | sc-200615B sc-200615 sc-200615A | 5 mg 10 mg 50 mg | $61.00 $83.00 $349.00 | 155 | |
Inhibits NF-κB; downregulates TAPT1 expression by suppressing promoter activity. | ||||||